Flinton Capital Management LLC increased its stake in Zoetis Inc (NYSE:ZTS) by 8.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 39,610 shares of the company’s stock after purchasing an additional 3,026 shares during the quarter. Flinton Capital Management LLC’s holdings in Zoetis were worth $2,854,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Zoetis in the fourth quarter valued at $108,000. Steward Partners Investment Advisory LLC acquired a new position in Zoetis in the third quarter worth $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares in the last quarter. Premia Global Advisors LLC acquired a new position in Zoetis in the fourth quarter worth $122,000. Finally, Icon Wealth Partners LLC acquired a new position in Zoetis in the fourth quarter worth $127,000. 92.35% of the stock is currently owned by institutional investors.
ZTS has been the topic of several research reports. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a research note on Saturday, January 13th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research note on Monday, January 8th. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target for the company in a report on Thursday, January 4th. Cowen set a $85.00 price target on Zoetis and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Craig Hallum reiterated a “buy” rating and set a $85.00 price objective (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $80.94.
Shares of ZTS traded down $2.55 during midday trading on Friday, hitting $80.97. The company’s stock had a trading volume of 2,752,329 shares, compared to its average volume of 2,550,576. Zoetis Inc has a one year low of $52.36 and a one year high of $85.73. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85. The firm has a market cap of $40,528.39, a price-to-earnings ratio of 33.74, a PEG ratio of 1.87 and a beta of 0.96.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. Zoetis’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS. research analysts forecast that Zoetis Inc will post 3.05 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is presently 20.83%.
In other Zoetis news, insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the sale, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The disclosure for this sale can be found here. Insiders have sold a total of 112,952 shares of company stock worth $9,219,843 over the last ninety days. Company insiders own 0.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/flinton-capital-management-llc-increases-stake-in-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.